Investor Relations, WE Buchan
| Role | Organisation | Sources |
|---|---|---|
| Investor and Media Relations (former) | Buchan Consulting | GBS Ventures (Wed 2 Sep 2015), GBS Ventures (Mon 31 Aug 2015) |
| Investor Relations | WE Buchan | GBS Ventures (Tue 12 Jun 2018), GBS Ventures (Wed 28 Feb 2018), GBS Ventures (Fri 5 May 2017), GBS Ventures (Fri 24 Feb 2017), GBS Ventures (Fri 27 Jan 2017), GBS Ventures (Thu 22 Dec 2016), GBS Ventures (Wed 8 Jun 2016) |
| Investor Relations | WE Buchan | GBS Ventures (Fri 31 Aug 2018), GBS Ventures (Fri 27 Apr 2018) |
Stories naming Kyahn Williamson. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Medical device maker AirXpanders completed a private placement first announced in August 2018, issuing shares to Vivo Ventures and its chairman Barry Cheskin to raise about US$3.4 million, notifying the ASX accordingly.
Medical device maker AirXpanders appoints US industry veteran Frank Grillo as chief executive, succeeding interim leader Scott Murcray, with co-founder Barry Cheskin welcoming the hire ahead of Grillo fronting July's investor call.
AirXpanders' quarterly update: steady revenue, cost cuts and headcount reductions, Scott Murcray interim CEO while the board searches for a permanent chief, and a planned move to Australian distributors.
ASX-listed medical device maker AirXpanders, based in California, released its 2017 full-year results, reporting growing AeroForm sales, a US$34 million equity placement, and a US$15 million debt facility with Oxford Finance.
US-based medical device maker AirXpanders, listed on the ASX, proposes adding Liz Hammack to its board as co-founder Teddy Shalon departs and fellow director Dennis Condon faces re-election at its May annual meeting.
ASX-listed medical device maker AirXpanders, based in California, has committed investors for a A$45 million private placement at A$0.92 per CDI, with Canaccord Genuity as sole lead manager, to fund its US commercial launch.
Also GBS Ventures·GBS Ventures
Breast reconstruction device maker AirXpanders gained US regulator clearance for its needle-free AeroForm tissue expander, enabling a January 2017 American launch; an amended CE Mark also covers an enhanced version.
ASX-listed breast reconstruction device maker AirXpanders secured commitments for a 20 million dollar placement at 76 cents per CDI, and appointed Scott Murcray CFO/COO ahead of its planned US launch.
Breast reconstruction device maker AirXpanders has lodged a 510(k) regulatory submission with US authorities for its needle-free AeroForm tissue expander, following positive clinical trial results, as it moves toward entering the American market.
ASX-listed breast reconstruction device maker AirXpanders reports its pivotal XPAND trial met its primary endpoint, with results to go to the US regulator and be presented at a plastic surgery meeting in Boston.